Antonio Cristiano1,2, Valentina Fortunati3, Fabio Cherubini3, Sergio Bernardini3,4,5, Marzia Nuccetelli3,4. 1. Department of Experimental Medicine, Tor Vergata University, Via Montpellier, 1, 00133, Rome, Italy. cristianoantonio93@hotmail.it. 2. Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy. cristianoantonio93@hotmail.it. 3. Department of Experimental Medicine, Tor Vergata University, Via Montpellier, 1, 00133, Rome, Italy. 4. Tor Vergata University Hospital, Rome, Italy. 5. Emerging Technologies Division, International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Milano, Italy.
Abstract
INTRODUCTION: Besides distinctive respiratory and digestive hallmarks, COVID-19 has been recently associated with a high prevalence of pro-inflammatory and hypercoagulable states known as "COVID-19 Associated Coagulopathy" (CAC), corresponding to a worsening in patients' conditions, whose causes are still to be elucidated. A link between anti-phospholipid antibodies (aPLs) and viral infections has long been suggested. APLs are assessed for anti-phospholipid syndrome (APS) diagnosis, characterized by thrombocytopenia, thrombosis, and coagulopathy. Furthermore, circulating immune complexes (CICs), arisen upon inflammatory responses and related immune dysregulation, can lead to endothelial cell damage and thrombotic complications. METHOD: We performed an extended panel including IgG/IgM anti-cardiolipin, IgG/IgM anti-β2-glycoprotein-1, coupled with IgG/IgM anti-prothrombin, IgG/IgM anti-annexin-V on two COVID-19 patient groups (early and late infection time), and a negative control group. IgG CIC analysis followed to evaluate inflammatory status, through a possible complement system activation. RESULTS: Our results showed low positive case percentage in IgG/IgM anti-cardiolipin and IgG/IgM anti-β2-glycoprotein-1 assays (4.54%, 6.25%, and 4.55%; in early infection group, late infection group, and control group, respectively); few positive cases in IgG/IgM anti-prothrombin and IgG/IgM anti-annexin-V immunoassays; and no IgG CIC positivity in any patient. CONCLUSIONS: In conclusion, our data show a low aPL prevalence, likely excluding an involvement in the pathogenesis of CAC. Interestingly, IgG/IgM anti-prothrombin and anti-annexin-V positive cases, detected in late infection group, suggest that aPLs could temporarily increase or could trigger a "COVID-19-induced-APS-like-syndrome" in predisposed patients. Key Points • To our knowledge, anti-prothrombin (aPT) antibodies, anti-annexin-V antibodies and CICs in COVID-19 patients have not been reported in the scientific literature. • Lack of uniformity and the low percentage of aCL/aβ2GP1 positivity preclude a putative role in CAC pathogenesis. • IgG/IgM anti-prothrombin and IgG/IgM anti-annexin-V data show that distribution of positive case number increases in late infection patients, significantly in anti-annexin-V results, suggesting a possible role for these anti-phospholipid antibodies in disease course. • aPLs can arise transiently in some patients with critical illness and SARS-CoV-2 infection (disappearing in a few weeks), as well as in other genetically predisposed patients; they could trigger a "COVID-19-induced-APS-like-syndrome".
INTRODUCTION: Besides distinctive respiratory and digestive hallmarks, COVID-19 has been recently associated with a high prevalence of pro-inflammatory and hypercoagulable states known as "COVID-19 Associated Coagulopathy" (CAC), corresponding to a worsening in patients' conditions, whose causes are still to be elucidated. A link between anti-phospholipid antibodies (aPLs) and viral infections has long been suggested. APLs are assessed for anti-phospholipid syndrome (APS) diagnosis, characterized by thrombocytopenia, thrombosis, and coagulopathy. Furthermore, circulating immune complexes (CICs), arisen upon inflammatory responses and related immune dysregulation, can lead to endothelial cell damage and thrombotic complications. METHOD: We performed an extended panel including IgG/IgM anti-cardiolipin, IgG/IgM anti-β2-glycoprotein-1, coupled with IgG/IgM anti-prothrombin, IgG/IgM anti-annexin-V on two COVID-19 patient groups (early and late infection time), and a negative control group. IgG CIC analysis followed to evaluate inflammatory status, through a possible complement system activation. RESULTS: Our results showed low positive case percentage in IgG/IgM anti-cardiolipin and IgG/IgM anti-β2-glycoprotein-1 assays (4.54%, 6.25%, and 4.55%; in early infection group, late infection group, and control group, respectively); few positive cases in IgG/IgM anti-prothrombin and IgG/IgM anti-annexin-V immunoassays; and no IgG CIC positivity in any patient. CONCLUSIONS: In conclusion, our data show a low aPL prevalence, likely excluding an involvement in the pathogenesis of CAC. Interestingly, IgG/IgM anti-prothrombin and anti-annexin-V positive cases, detected in late infection group, suggest that aPLs could temporarily increase or could trigger a "COVID-19-induced-APS-like-syndrome" in predisposed patients. Key Points • To our knowledge, anti-prothrombin (aPT) antibodies, anti-annexin-V antibodies and CICs in COVID-19 patients have not been reported in the scientific literature. • Lack of uniformity and the low percentage of aCL/aβ2GP1 positivity preclude a putative role in CAC pathogenesis. • IgG/IgM anti-prothrombin and IgG/IgM anti-annexin-V data show that distribution of positive case number increases in late infection patients, significantly in anti-annexin-V results, suggesting a possible role for these anti-phospholipid antibodies in disease course. • aPLs can arise transiently in some patients with critical illness and SARS-CoV-2 infection (disappearing in a few weeks), as well as in other genetically predisposed patients; they could trigger a "COVID-19-induced-APS-like-syndrome".
Authors: Marco Ranucci; Andrea Ballotta; Umberto Di Dedda; Ekaterina Bayshnikova; Marco Dei Poli; Marco Resta; Mara Falco; Giovanni Albano; Lorenzo Menicanti Journal: J Thromb Haemost Date: 2020-05-06 Impact factor: 5.824
Authors: Sigurd F Lax; Kristijan Skok; Peter Zechner; Harald H Kessler; Norbert Kaufmann; Camillo Koelblinger; Klaus Vander; Ute Bargfrieder; Michael Trauner Journal: Ann Intern Med Date: 2020-05-14 Impact factor: 25.391
Authors: Saskia Middeldorp; Michiel Coppens; Thijs F van Haaps; Merijn Foppen; Alexander P Vlaar; Marcella C A Müller; Catherine C S Bouman; Ludo F M Beenen; Ruud S Kootte; Jarom Heijmans; Loek P Smits; Peter I Bonta; Nick van Es Journal: J Thromb Haemost Date: 2020-07-27 Impact factor: 5.824
Authors: Dominic Wichmann; Jan-Peter Sperhake; Marc Lütgehetmann; Stefan Steurer; Carolin Edler; Axel Heinemann; Fabian Heinrich; Herbert Mushumba; Inga Kniep; Ann Sophie Schröder; Christoph Burdelski; Geraldine de Heer; Axel Nierhaus; Daniel Frings; Susanne Pfefferle; Heinrich Becker; Hanns Bredereke-Wiedling; Andreas de Weerth; Hans-Richard Paschen; Sara Sheikhzadeh-Eggers; Axel Stang; Stefan Schmiedel; Carsten Bokemeyer; Marylyn M Addo; Martin Aepfelbacher; Klaus Püschel; Stefan Kluge Journal: Ann Intern Med Date: 2020-05-06 Impact factor: 25.391
Authors: Natalia Zubarovskaya; Irene Hofer-Popow; Marco Idzko; Oskar A Haas; Anita Lawitschka Journal: Front Pediatr Date: 2022-01-14 Impact factor: 3.418
Authors: Huriye Ercan; Waltraud Cornelia Schrottmaier; Anita Pirabe; Anna Schmuckenschlager; David Pereyra; Jonas Santol; Erich Pawelka; Marianna T Traugott; Christian Schörgenhofer; Tamara Seitz; Mario Karolyi; Jae-Won Yang; Bernd Jilma; Alexander Zoufaly; Alice Assinger; Maria Zellner Journal: Front Cardiovasc Med Date: 2021-11-11
Authors: Marc Emmenegger; Sreedhar Saseendran Kumar; Vishalini Emmenegger; Tomas Malinauskas; Thomas Buettner; Laura Rose; Peter Schierack; Martin F Sprinzl; Clemens J Sommer; Karl J Lackner; Adriano Aguzzi; Dirk Roggenbuck; Katrin B M Frauenknecht Journal: PLoS Pathog Date: 2021-12-03 Impact factor: 6.823
Authors: Daniel Bertin; Alexandre Brodovitch; Alexandre Lopez; Robin Arcani; Grace M Thomas; Abdou Beziane; Samuel Weber; Benjamin Babacci; Xavier Heim; Louise Rey; Marc Leone; Jean Louis Mege; Nathalie Bardin Journal: Sci Rep Date: 2022-07-22 Impact factor: 4.996